These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37301978)

  • 1. Evaluating the One-Year Efficacy of Combined Anti-VEGF and Dexamethasone Implant Treatment for Macular Edema in Retinal Vein Occlusions.
    Ren F; Gong H; Zhang H; Zhang X; Liu X; Li J; Zhang G
    Med Sci Monit; 2023 Jun; 29():e939277. PubMed ID: 37301978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
    Hu Q; Li H; Xu W; Du Y; Ma C; He J
    Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.
    Blanc J; Deschasse C; Kodjikian L; Dot C; Bron AM; Creuzot-Garcher C
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1441-1448. PubMed ID: 29855706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study.
    Dugel PU; Capone A; Singer MA; Dreyer RF; Dodwell DG; Roth DB; Shi R; Walt JG; Scott LC; Hollander DA;
    BMC Ophthalmol; 2015 Sep; 15():118. PubMed ID: 26337664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France.
    Korobelnik JF; Kodjikian L; Delcourt C; Gualino V; Leaback R; Pinchinat S; Velard ME
    Graefes Arch Clin Exp Ophthalmol; 2016 Dec; 254(12):2307-2318. PubMed ID: 27286894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Serum Inflammation-Based Factors in Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion and Its Subtypes.
    Rao J; Wu N; Qu X; Hu Y; Wu Y; Cheng Y; Yan L; Huang H; Li S; Shi L; Wu X
    Ophthalmic Res; 2021; 64(2):237-245. PubMed ID: 32506058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous intravitreal dexamethasone and aflibercept for refractory macular edema secondary to retinal vein occlusion.
    Giuffrè C; Cicinelli MV; Marchese A; Coppola M; Parodi MB; Bandello F
    Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):787-793. PubMed ID: 31897703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal Dexamethasone Implant Has Better Retinal Perfusion than Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion: A Five-Year Real-World Study.
    Zhang M; Liu Y; Song M; Yu Y; Ruan S; Zheng K; Wang F; Sun X
    Ophthalmic Res; 2023; 66(1):247-258. PubMed ID: 36215955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Injection of Anti-Vascular Endothelial Growth Factors Combined with Corticosteroids for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: A Systematic Review and Meta-Analysis.
    Namvar E; Yasemi M; Nowroozzadeh MH; Ahmadieh H
    Semin Ophthalmol; 2024 Jan; 39(1):109-119. PubMed ID: 37621098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of dexamethasone intravitreal implant with intravitreal anti-VEGF injections for the treatment of macular edema secondary to branch retinal vein occlusion: A meta-analysis.
    Ji K; Zhang Q; Tian M; Xing Y
    Medicine (Baltimore); 2019 May; 98(22):e15798. PubMed ID: 31145307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
    Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monthly microperimetry (MP1) measurement of macular sensitivity after dexamethasone implantation (Ozurdex) in retinal vein occlusions.
    Winterhalter S; Vom Brocke GA; Klamann MK; Müller B; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2015 Nov; 253(11):1873-82. PubMed ID: 25576170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant.
    Castro-Navarro V; Monferrer-Adsuara C; Navarro-Palop C; Montero-Hernández J; Cervera-Taulet E
    BMC Ophthalmol; 2022 Apr; 22(1):191. PubMed ID: 35473615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life study of the use of anti-VEGF therapy versus dexamethasone implant for treatment of macular edema in retinal vein occlusion.
    de Salles MC; Epstein D
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2653-2660. PubMed ID: 33738625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of dexamethasone intravitreal implant (Ozurdex) for the treatment of persistent macular edema secondary to retinal vein occlusion in eyes previously treated with anti-vascular endothelial growth factors.
    Tservakis I; Koutsandrea C; Papaconstantinou D; Paraskevopoulos T; Georgalas I
    Curr Drug Saf; 2015; 10(2):145-51. PubMed ID: 25092480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial.
    Eter N; Mohr A; Wachtlin J; Feltgen N; Shirlaw A; Leaback R;
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):77-87. PubMed ID: 27460280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population.
    Gu X; Yu X; Song S; Dai H
    Ophthalmic Res; 2017; 58(1):8-14. PubMed ID: 28334720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study.
    Singer MA; Capone A; Dugel PU; Dreyer RF; Dodwell DG; Roth DB; Shi R; Walt JG; Scott LC; Hollander DA;
    BMC Ophthalmol; 2015 Apr; 15():33. PubMed ID: 25885285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study.
    Feltgen N; Hattenbach LO; Bertelmann T; Callizo J; Rehak M; Wolf A; Berk H; Eter N; Lang GE; Pielen A; Schmitz-Valckenberg S; Quiering C; Rose U; Hoerauf H;
    Acta Ophthalmol; 2018 Dec; 96(8):e933-e941. PubMed ID: 29855153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study.
    Li X; Wang N; Liang X; Xu G; Li XY; Jiao J; Lou J; Hashad Y;
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):59-69. PubMed ID: 29119239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.